Immunochemotherapy
AACR 2019: Pembrolizumab combined with chemotherapy improves survival of patients with NSCLC with brain and liver metastases
With the KEYNOTE-189 study, combined immunochemotherapy became the new first-line standard for metastastatic nonsquamous non-small-cell lung cancer. A recent update of the trial now reveals that patients with brain or liver metastasis benefit as well as patients without metastases.
